Education
About Us
Working with TipRanks
Follow Us
Arno Therapeutics Inc (ARNI)
OTHER OTC:ARNI
ARNI Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EST
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume800.00
Average Volume (3M)615.78K
Market Cap
$49.00
Enterprise ValueN/A
Total Cash (Recent Filing)$2.12M
Total Debt (Recent Filing)$5.09K
Price to Earnings (P/E)―
Beta-40.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding49,350,000
10 Day Avg. Volume615,780
30 Day Avg. Volume615,780
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ARNI FAQ
What was Arno Therapeutics Inc’s price range in the past 12 months?
Arno Therapeutics Inc lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is Arno Therapeutics Inc’s market cap?
Arno Therapeutics Inc’s market cap is $49.00.
When is Arno Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Arno Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Arno Therapeutics Inc overvalued?
According to Wall Street analysts Arno Therapeutics Inc’s price is currently Overvalued.
Does Arno Therapeutics Inc pay dividends?
Arno Therapeutics Inc does not currently pay dividends.
What is Arno Therapeutics Inc’s EPS estimate?
Arno Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arno Therapeutics Inc have?
Arno Therapeutics Inc has 49,350,000 shares outstanding.
What happened to Arno Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arno Therapeutics Inc?
Currently, no hedge funds are holding shares in ARNI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Arno Therapeutics Inc
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
8.47% Other Institutional Investors
91.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---